Thermo Fisher acquires PeproTech in US$1.85 billion deal

Thermo Fisher Scientific Inc (MA, USA) has announced its acquisition of PeproTech, Inc. (NJ, USA), a leading developer and manufacturer of recombinant proteins, including cytokines and growth factors. These resources are extensively used in the development of cell and gene therapies.

The US$1.85 billion investment should advance Thermo Fisher’s cell culture media portfolio – an essential resource in the evolution of novel regenerative therapies.

“PeproTech will be an excellent strategic fit within our biosciences business and will allow us to even better serve our pharma and biotech customers by adding new capabilities to our existing offering,” commented Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “In combination with our proprietary bioprocessing and cell culture technologies, this complementary transaction positions us to partner with our customers to drive the evolution of the fast-growing market for cell and gene therapies. By leveraging our commercial reach, we will be able to efficiently grow the PeproTech business and generate attractive financial results all while furthering our Mission to enable our customers to make the world healthier, cleaner and safer.”

PeproTech will be integrated into Thermo Fisher’s Life Sciences Solutions Segment.

Bob Goldman, president and co-founder of PeproTech, concluded, “We are pleased to join Thermo Fisher given their team’s outstanding industry leadership and shared commitment to develop innovative therapies that improve patient outcomes. PeproTech’s reputation for unparalleled product consistency and quality directly aligns with that of Thermo Fisher’s, and we look forward to building on our success as part of the world leader in serving science.”